Hemorrhoids and Rectal Cancer: A Systematic Review of Clinical Overlap, Diagnostic Misclassification, and Early Detection Strategies for Primary Care Authors: Mei Tu, Wei Jiang, Yangfeng Huang Published: 2026 ABSTRACT AbstractHemorrhoidal disease (HD) and rectal cancer (RC) are common anorectal disorders with overlapping clinical symptoms, including rectal bleeding, altered bowel habits, and anorectal discomfort. This similarity leads to frequent misdiagnosis of RC as HD, and early diagnosis is essential for improving survival and quality of life in patients with RC. This systematic review aimed to summarize overlapping features, analyze causes of misdiagnosis, and review advances in early detection to provide practical guidance for primary care. A literature search was performed in PubMed, Embase, and Web of Science, covering publications from January 2018 to February 2026. We included systematic reviews, meta-analyses, randomized controlled trials, cohort studies, case-control studies, and clinical guidelines that addressed clinical association, differential diagnosis, or early detection of HD and RC, with case series requiring ≥10 participants; single case reports, conference abstracts, animal studies, and low-quality non-core journals were excluded. Two reviewers independently extracted data and assessed study quality using AMSTAR 2, Cochrane RoB, Newcastle-Ottawa Scale, and AGREE II, with disagreements resolved by consensus. Due to substantial heterogeneity across studies, a narrative qualitative synthesis was performed, grouping findings by the three review questions. Forty-six moderate- to high-quality studies were included in the analysis. Rectal bleeding was the most frequent overlapping symptom, followed by altered bowel habits and anorectal discomfort. Warning signs suggestive of RC included dark red blood per rectum, persistent anorectal pain, and unexplained weight loss. Major causes of misdiagnosis include clinical inertia, insufficient use of digital rectal examination, and limited access to endoscopy, especially in primary care settings. Limitations include scarcity of randomized controlled trials in diagnostic research, limited primary care data, and preliminary evidence for emerging technologies. Overlapping symptoms remain the main cause of misdiagnosis of RC. Increased clinical awareness, standardized diagnostic procedures, and proper screening tools can significantly reduce diagnostic errors. This review offers evidence-based support for differential diagnosis and early detection of RC in routine clinical practice. Introduction Hemorrhoidal disease (HD), commonly referred to as hemorrhoid, is the most frequently diagnosed benign anorectal condition worldwide. Its global prevalence ranges from 4.4% to 36.4%.1 It arises from pathological dilation and engorgement of the anal vascular cushions, typically presenting with bleeding, prolapse, and discomfort.2 Although benign in nature, HD can substantially impair quality of life. In contrast, rectal cancer (RC) is the third most common malignancy globally, with approximately 1.1 million new cases and 550,000 deaths annually.3 Prognosis is closely tied to disease stage at diagnosis. Five-year survival rates exceed 80% for stage I–II disease but fall below 10% for stage IV disease,4 underscoring the critical importance of early detection and accurate diagnosis. One of the greatest challenges in the management of anorectal disorders is the considerable overlap in the symptoms between HD and RC. Rectal bleeding is the most frequent shared manifestation, occurring in a large proportion of patients with HD and in 55–70% of those with early-stage RC. Additional symptoms, such as changes in bowel habits and tenesmus, are also common to both conditions, further complicating clinical differentiation.4 Recent meta-analytic data indicate that rectal cancer is misdiagnosed as hemorrhoids in 15% to 45% of cases, with the highest rates observed in primary care settings and among younger patients.5 Improving the diagnostic skills of primary care clinicians and ensuring access to basic diagnostic tools are therefore essential to increasing early detection rates.6 The consequences of misdiagnosis extend beyond delayed cancer treatment. As the disease progresses from early to locally advanced or metastatic stages, the likelihood of curative resection declines sharply, and survival outcomes worsen considerably.7 In addition, diagnostic delays impose unnecessary psychological distress on patients and increase healthcare expenditures.8 Enhancing clinicians’ ability to distinguish between these two conditions, identifying the root causes of misdiagnosis, and implementing efficient screening strategies are thus key priorities for improving patient outcomes and optimizing the use of healthcare resources.9 In this systematic review, we addressed three central questions: How closely do the symptoms of HD and RC overlap? Why is rectal cancer frequently misdiagnosed as a hemorrhoid? How can primary care practitioners differentiate between these two? By synthesizing current high-quality evidence, we analyzed the causes and consequences of misdiagnosis, reviewed contemporary early detection strategies, and provided practical guidance tailored to the primary care setting where misdiagnosis is most prevalent. Methods This systematic review was conducted in accordance with the PRISMA 2020 guidelines. No ethical approval was obtained for this study. Literature Search Strategy A literature search was performed on April 5, 2026, across three electronic databases: PubMed, Embase, and Web of Science. The search period was limited to January 1, 2018, through February 28, 2026. A combination of MeSH terms and free-text keywords was used, including “hemorrhoids,” “rectal cancer,” “clinical overlap,” “misdiagnosis,” and “early screening.” Full search strategies for all databases, including controlled vocabulary and field tags, are provided in Supplementary Table 1. Study Questions and Methodological Approach This review was designed to address three predefined questions: (1) How closely do the symptoms of HD and RC overlap? (2) Why is RC frequently misdiagnosed as HD? (3) How can primary care practitioners differentiate between these two conditions? A unified literature search and screening process was conducted to identify all relevant studies addressing any of these questions. Following full-text retrieval, studies were categorized by the primary question they addressed, and data extraction and synthesis were performed separately for each question category. Studies that provided information relevant to multiple questions were categorized accordingly and their data were extracted for each applicable domain. Inclusion and Exclusion Criteria Studies were eligible if they addressed clinical association, differential diagnosis, or early detection of HD and RC. Eligible designs included systematic reviews, meta-analyses, RCTs, cohort studies, case-control studies, and clinical guidelines. Only English-language peer-reviewed articles with complete data were included, and the case series required ≥10 participants. The exclusion criteria included duplicate publications, single case reports, conference abstracts, studies lacking original data, animal studies, and low-quality non-core journals. Study Selection According to the PRISMA 2020 guidelines, the literature selection process was performed as follows. A total of 1268 records were initially retrieved from PubMed, Embase, and Web of Science. After removing 217 duplicate publications, 1051 records remained. After screening the titles and abstracts, 963 irrelevant articles were excluded. The remaining 88 articles were assessed through full-text reading. Among them, 41 articles were excluded for the following reasons: single case reports (n=8), conference abstracts (n=11), animal experiments (n=7), insufficient original data (n=9), and low-quality non-core journals (n=6). Finally, 46 eligible studies were included in this systematic review. In accordance with PRISMA 2020 reporting guidelines, a flow diagram summarizing the identification, screening, eligibility, and inclusion stages, along with the reasons for exclusion of full-text articles, is provided in Figure 1. Representative examples of excluded full-text articles with reasons for exclusion are provided in Supplementary Table 2.Figure 1PRISMA 2020 flow diagram of study selection. The diagram summarizes the identification, screening, eligibility, and inclusion stages, along with the reasons for exclusion of full-text articles, as described in Study Selection.A flowchart of study selection stages: identification, screening, eligibility and inclusion.The flowchart outlines the study selection process according to PRISMA 2020 guidelines. It begins with identification, where records are identified through database searching, totaling 1268 records. After removing 217 duplicates, 1051 records remain. Screening follows, with records screened by title and abstract, resulting in 963 exclusions. Eligibility is assessed through full-text reading of 88 articles, with 41 excluded for reasons such as single case reports, conference abstracts without full data, animal experiments, insufficient original clinical data and low-quality non-core journals. Finally, 46 studies are included in the qualitative synthesis. PRISMA 2020 flow diagram of study selection. The diagram summarizes the identification, screening, eligibility, and inclusion stages, along with the reasons for exclusion of full-text articles, as described in Study Selection. Data Extraction Two reviewers (MT and WJ) independently extracted data from all included studies using a standardized data extraction form. The following information was collected: first author, year, country, study design, sample size, participant characteristics, definitions of HD and RC, clinical features reported, diagnostic methods used, misdiagnosis rates, and key findings relevant to the three review questions. Disagreements between reviewers were resolved through discussion, with consultation of a third reviewer (YH). When consensus could not be reached. When data were unclear or missing, we attempted to contact the corresponding authors by email; however, no additional data were obtained. No automation tools were used in the data extraction or study selection processes. Quality Assessment The methodological quality of included studies was assessed using validated tools appropriate for each study design: AMSTAR 2 for systematic reviews, the Cochrane Risk of Bias tool for randomized controlled trials, the Newcastle-Ottawa Scale for observational studies (cohort and case-control), and AGREE II for clinical guidelines. Two reviewers (MT and WJ) independently applied these tools; discrepancies were resolved by consensus. For AMSTAR 2, studies were rated as high, moderate, low, or critically low based on the number of critical and non-critical weaknesses. For the Cochrane RoB tool, studies were judged as low risk, some concerns, or high risk across domains including randomization, allocation concealment, blinding, and completeness of outcome data. For the Newcastle-Ottawa Scale, studies scoring ≥7 were considered high quality, 5–6 moderate quality, and <5 low quality. For AGREE II, domain scores ≥60% were considered adequate. Only studies rated as moderate or high quality were included in this review; low-quality studies were excluded. A summary of quality assessments for all included studies is presented in Supplementary Table 3. Data Synthesis Due to substantial clinical and methodological heterogeneity across the included studies (including variations in study design, participant populations, definitions of HD and RC, and outcome measures), a quantitative meta-analysis was not feasible. Instead, a narrative qualitative synthesis was performed following the guidance of the Cochrane Handbook for Systematic Reviews of Interventions. Findings were grouped by the three review questions: (1) clinical overlap between HD and RC, (2) causes and consequences of misdiagnosis, and (3) early detection strategies. Within each question category, studies were further grouped by study design and key findings were summarized descriptively. Key themes and patterns were identified across studies, with particular attention to consistent findings and areas of disagreement. Subgroup descriptions were considered by patient age (<40 vs ≥40 years), study setting (primary care vs specialist), and geographic region, where data permitted. Registration PROSPERO registration number: CRD420261357670 (registered April 1, 2026). Outcomes The following outcomes were predefined for data extraction and synthesis: Primary Outcomes (1)Prevalence and characteristics of overlapping clinical symptoms between HD and RC (including rectal bleeding, altered bowel habits, anorectal discomfort, and mucous discharge).(2)Rates and causes of misdiagnosis of RC as HD.(3)Diagnostic accuracy of physical examination (DRE and anoscopy), endoscopic procedures, and non-invasive tests for distinguishing HD from RC. (1)Prevalence and characteristics of overlapping clinical symptoms between HD and RC (including rectal bleeding, altered bowel habits, anorectal discomfort, and mucous discharge). Prevalence and characteristics of overlapping clinical symptoms between HD and RC (including rectal bleeding, altered bowel habits, anorectal discomfort, and mucous discharge). (2)Rates and causes of misdiagnosis of RC as HD. Rates and causes of misdiagnosis of RC as HD. (3)Diagnostic accuracy of physical examination (DRE and anoscopy), endoscopic procedures, and non-invasive tests for distinguishing HD from RC. Diagnostic accuracy of physical examination (DRE and anoscopy), endoscopic procedures, and non-invasive tests for distinguishing HD from RC. Secondary Outcomes (1)Clinical and prognostic consequences of diagnostic delay.(2)Populations at increased risk of misdiagnosis.(3)Performance characteristics of emerging diagnostic technologies (AI-assisted endoscopy, ctDNA, etc). (1)Clinical and prognostic consequences of diagnostic delay. Clinical and prognostic consequences of diagnostic delay. (2)Populations at increased risk of misdiagnosis. Populations at increased risk of misdiagnosis. (3)Performance characteristics of emerging diagnostic technologies (AI-assisted endoscopy, ctDNA, etc). Performance characteristics of emerging diagnostic technologies (AI-assisted endoscopy, ctDNA, etc). Results Study Characteristics and Quality Assessment A total of 46 studies met the inclusion criteria and were included in this systematic review. The included studies comprised 12 systematic reviews or meta-analyses, 4 randomized controlled trials (including long-term follow-up reports), 11 cohort studies, 3 case-control studies, 6 clinical guidelines, and 10 narrative reviews or epidemiological reports. Publication dates ranged from 2018 to 2026, reflecting recent evidence in this field. The majority of studies were conducted in high-income countries (n=34), with fewer studies from middle-income settings (n=12); notably, fewer than 30% of the included studies were performed in primary care settings, highlighting a gap in evidence directly applicable to the point of care where most diagnostic decisions occur. Quality assessment results are summarized in Table 1 (overview of key characteristics and overall ratings) and Supplementary Table 3 (detailed domain-level assessments). Overall, 31 studies were rated as high quality and 15 as moderate quality; no low-quality studies were included in this review. For systematic reviews and meta-analyses assessed with AMSTAR 2, the most common strengths included comprehensive search strategies and appropriate statistical synthesis, while occasional weaknesses involved incomplete reporting of excluded studies or lack of protocol registration. For observational studies assessed with the Newcastle-Ottawa Scale, common limitations included inadequate control for confounding and incomplete outcome data, which were the primary reasons for moderate quality ratings. For clinical guidelines assessed with AGREE II, all scored above 60% in key domains, with high scores in scope and clarity but more variable scores in applicability. Table 1Summary of Included Studies: Design, Sample Size, Main Findings, and Quality RatingFirst AuthorYearStudy DesignSampleSizeMain FindingsQualityRatingEbrahimi P2026Systematic review / Meta-analysis–Global prevalence of HD: 4.4%–36.4%HighAshburn JH2025Review–Clinical management of hemorrhoidal diseaseHighBray F2024Epidemiological report–Global incidence and mortality of rectal cancerHighDekker E2019Review–Comprehensive review of colorectal cancerHighSiegel RL2023Epidemiological report–Colorectal cancer statisticsHighMksyartinian P2024Qualitative study–Patient experiences with family practitionersModerateBiller LH2021Review–Diagnosis and treatment of metastatic CRCHighRamanathan A2024Retrospective study–Value of DRE in early-onset rectal cancerModerateBates KR2025Retrospective cohort–Low rates of DRE useModerateCampbell KA2024Retrospective cohort–Colonoscopy completion rates for rectal bleedingModerateWooldrage K2024RCT with long-term follow-up–Efficacy of flexible sigmoidoscopy screeningHighTan S2025Network meta-analysis50,834AI-assisted colonoscopy increased ADR by 20%HighQutob IA2025Meta-analysis (38 RCTs)29,745AI-assisted colonoscopy: ADR RR 1.19HighSultany A2025Systematic review / Meta-analysis11,267AI improved polyp detection rateHighHan C2024Meta-analysis of RCTs–Endoscopy reduced CRC incidence and mortalityHighChandrapalan S2021Meta-analysis–Volatile organic compound analysis to aid FITModerateCheney CP2025Systematic review / Meta-analysis–FIT performance in non-high-income countriesHighGerrard AD2024Systematic review / Meta-analysis–Repeat FIT increased sensitivityHighMo S2023Cohort study–ctDNA methylation assay for early detectionHighKang D2025Case-control study–ctDNA methylation + FOBTModerateKahn CL2025Cohort study–ctDNA + FIT dual testingModerateNess RM2024Guideline–NCCN colorectal cancer screening guidelinesHighNCCN2026Guideline–NCCN screening guidelines V2.2026HighIssaka RB2023Expert review–AGA risk stratification guidanceHighNotes: This table summarises the key characteristics of the included studies. A detailed quality assessment for each study is provided in Supplementary Table 3. The “Quality rating” was derived from the validated tools described in Quality Assessment (AMSTAR 2, Cochrane RoB, Newcastle-Ottawa Scale, or AGREE II). Studies rated as “Moderate” or “High” were included; “Low”-quality studies were excluded. “–” indicates that the information was not reported or not applicable. Table 1Summary of Included Studies: Design, Sample Size, Main Findings, and Quality RatingFirst AuthorYearStudy DesignSampleSizeMain FindingsQualityRatingEbrahimi P2026Systematic review / Meta-analysis–Global prevalence of HD: 4.4%–36.4%HighAshburn JH2025Review–Clinical management of hemorrhoidal diseaseHighBray F2024Epidemiological report–Global incidence and mortality of rectal cancerHighDekker E2019Review–Comprehensive review of colorectal cancerHighSiegel RL2023Epidemiological report–Colorectal cancer statisticsHighMksyartinian P2024Qualitative study–Patient experiences with family practitionersModerateBiller LH2021Review–Diagnosis and treatment of metastatic CRCHighRamanathan A2024Retrospective study–Value of DRE in early-onset rectal cancerModerateBates KR2025Retrospective cohort–Low rates of DRE useModerateCampbell KA2024Retrospective cohort–Colonoscopy completion rates for rectal bleedingModerateWooldrage K2024RCT with long-term follow-up–Efficacy of flexible sigmoidoscopy screeningHighTan S2025Network meta-analysis50,834AI-assisted colonoscopy increased ADR by 20%HighQutob IA2025Meta-analysis (38 RCTs)29,745AI-assisted colonoscopy: ADR RR 1.19HighSultany A2025Systematic review / Meta-analysis11,267AI improved polyp detection rateHighHan C2024Meta-analysis of RCTs–Endoscopy reduced CRC incidence and mortalityHighChandrapalan S2021Meta-analysis–Volatile organic compound analysis to aid FITModerateCheney CP2025Systematic review / Meta-analysis–FIT performance in non-high-income countriesHighGerrard AD2024Systematic review / Meta-analysis–Repeat FIT increased sensitivityHighMo S2023Cohort study–ctDNA methylation assay for early detectionHighKang D2025Case-control study–ctDNA methylation + FOBTModerateKahn CL2025Cohort study–ctDNA + FIT dual testingModerateNess RM2024Guideline–NCCN colorectal cancer screening guidelinesHighNCCN2026Guideline–NCCN screening guidelines V2.2026HighIssaka RB2023Expert review–AGA risk stratification guidanceHighNotes: This table summarises the key characteristics of the included studies. A detailed quality assessment for each study is provided in Supplementary Table 3. The “Quality rating” was derived from the validated tools described in Quality Assessment (AMSTAR 2, Cochrane RoB, Newcastle-Ottawa Scale, or AGREE II). Studies rated as “Moderate” or “High” were included; “Low”-quality studies were excluded. “–” indicates that the information was not reported or not applicable. Summary of Included Studies: Design, Sample Size, Main Findings, and Quality Rating Notes: This table summarises the key characteristics of the included studies. A detailed quality assessment for each study is provided in Supplementary Table 3. The “Quality rating” was derived from the validated tools described in Quality Assessment (AMSTAR 2, Cochrane RoB, Newcastle-Ottawa Scale, or AGREE II). Studies rated as “Moderate” or “High” were included; “Low”-quality studies were excluded. “–” indicates that the information was not reported or not applicable. Clinical Overlap Between Hemorrhoidal Disease and Rectal Cancer (Question 1) The clinical presentations of HD and RC overlap substantially, and early-stage rectal cancer often presents with nonspecific symptoms that can be easily overlooked.10 Nonetheless, careful attention to symptom characteristics and a high index of suspicion can reveal key differentiating features that support accurate diagnosis.10 The anatomical locations and morphological differences between hemorrhoidal disease and rectal cancer are illustrated in Figure 2.Figure 2Anatomical and morphological comparison between hemorrhoidal disease and rectal cancer. Schematic diagram showing the anatomical location and typical morphological differences between hemorrhoidal disease and rectal cancer in the anorectal region. Key distinctions in lesions, bleeding manifestations and tissue texture are marked. This schematic illustration was generated with the assistance of KnowS Professional Edition 8X; the anatomical relationships and pathological features depicted are based on the authors’ synthesis of the included literature.Comparison of hemorrhoidal disease and rectal cancer anatomy and symptoms. Anatomical and morphological comparison between hemorrhoidal disease and rectal cancer. Schematic diagram showing the anatomical location and typical morphological differences between hemorrhoidal disease and rectal cancer in the anorectal region. Key distinctions in lesions, bleeding manifestations and tissue texture are marked. This schematic illustration was generated with the assistance of KnowS Professional Edition 8X; the anatomical relationships and pathological features depicted are based on the authors’ synthesis of the included literature. Overlapping Symptoms Rectal bleeding, altered bowel habits, anorectal discomfort, and mucous discharge are the most common symptoms. None is specific to either condition, making differentiation particularly challenging in primary care settings where advanced diagnostic equipment may not be readily available.11 In HD, bleeding is typically bright red, on the stool surface or toilet paper, painless, and often triggered by constipation or straining.12 Early low-lying rectal cancers (within 10 cm of the anal verge) can also present with bright red blood that has not been mixed with stool, creating a picture that closely resembles bleeding from hemorrhoids.12 Altered bowel habits were non-specific. Patients with HD may experience constipation or straining due to discomfort, which in turn exacerbates their hemorrhoidal symptoms.2 In early RC, tumor-induced irritation of the rectal mucosa frequently leads to increased stool frequency, urgency, or alternating constipation and diarrhea, sometimes accompanied by tenesmus. Although tenesmus can occur in HD from prolapsing hemorrhoidal tissue, in RC, it is caused by direct tumor infiltration or mass effect.4 Anorectal discomfort and mucous discharge also occurred under both the conditions. In HD, pruritus, burning, and a sensation of fullness are often related to mucus leakage from prolapsed internal hemorrhoids.2 In RC, discomfort tends to be more persistent and may manifest as a dull ache or abdominal distension from tumor compression or local invasion. Mucus in HD is typically clear or whitish, whereas RC may produce a mucoid or purulent discharge mixed with blood.12,13 Warning Signs Suggestive of Malignancy Despite symptom overlap, several clinical features should raise suspicion for RC, especially in primary care.14 The nature of bleeding is a critical differentiator: RC bleeding is often dark red or “mucoid,” admixed with stool, and may occur without an identifiable trigger. Hemorrhoidal bleeding is classically bright red, well-circumscribed, and linked to constipation or straining.4 Persistent anorectal pain was a warning sign. Pain associated with RC tends to be constant, deep-seated, and unresponsive to conservative measures, whereas hemorrhoidal pain is usually intermittent and improves with supportive care.2 Systemic symptoms—unexplained weight loss, fatigue, or anemia—are common in RC but rare in isolated HD.15 As the tumor enlarges, it may cause progressive bowel obstruction; such findings cannot be attributed to HD alone.7 Age > 40 years and a family history of colorectal cancer further increase the likelihood of malignancy, and in such patients, even atypical symptoms should prompt a thorough evaluation to exclude RC.16 Key Distinguishing Features Between HD and RC Important differences exist in the disease course, symptom triggers, and physical examination findings (Table 2). HD follows a chronic, relapsing pattern, with symptoms responding to conservative management.2 RC follows a progressive trajectory, and symptoms do not improve with conservative treatment.4 Symptoms also differ: HD symptoms are often associated with low-fiber diets and constipation, whereas RC symptoms arise without clear precipitating factors.12,17 Table 2Clinical Overlap and Differential Diagnosis of Hemorrhoidal Disease and Rectal CancerClinical FeatureHemorrhoidal Disease (HD)Rectal Cancer (RC)Priority for Primary CareRectal bleedingBright red, painless; on surface of stool or toilet paper; triggered by straining/constipationEarly: bright red (low-lying tumors); Advanced: dark red or mucoid, mixed with stool, intermittent/persistent, no clear triggerHighAltered bowel habitsConstipation or straining due to discomfort; intermittent, improves with conservative carePersistent diarrhea, constipation, or alternating pattern; urgency, tenesmus; progressive worseningHighAnorectal discomfortIntermittent itching, burning, or pelvic heaviness; relieved by sitz baths or topical therapyPersistent dull or sharp pain, abdominal fullness; unresponsive to conservative measuresMediumSystemic symptomsRare; occasional weight loss or anemia only with chronic severe bleeding (very uncommon)Common: unexplained weight loss, fatigue, anemia, anorexiaHighPhysical examination (DRE/anoscopy)Soft, compressible vascular cushions; smooth surface; no fixed massHard, irregular, fixed mass; ulceration may be visible; guaiac-positive gloveHighDisease courseChronic, relapsing; symptoms improve with conservative treatmentProgressive; no improvement with conservative therapyMediumNotes: Clinical features were selected based on their frequency of reporting across the included studies (≥30% of studies reporting the feature) and their clinical relevance to the differential diagnosis. Differences in clinical presentation between HD and RC were determined by synthesizing findings from comparative studies and systematic reviews that reported feature-specific prevalence or characteristics. Priority levels (“High”/“edium”) were assigned based on: (1) the strength of evidence supporting the feature’s discriminatory value (number of studies, consistency of findings), (2) clinical utility in primary care settings (ease of assessment, availability of bedside testing), and (3) potential impact on patient outcomes if the feature is overlooked. High-priority features are those with strong evidence and direct implications for timely referral. Table 2Clinical Overlap and Differential Diagnosis of Hemorrhoidal Disease and Rectal CancerClinical FeatureHemorrhoidal Disease (HD)Rectal Cancer (RC)Priority for Primary CareRectal bleedingBright red, painless; on surface of stool or toilet paper; triggered by straining/constipationEarly: bright red (low-lying tumors); Advanced: dark red or mucoid, mixed with stool, intermittent/persistent, no clear triggerHighAltered bowel habitsConstipation or straining due to discomfort; intermittent, improves with conservative carePersistent diarrhea, constipation, or alternating pattern; urgency, tenesmus; progressive worseningHighAnorectal discomfortIntermittent itching, burning, or pelvic heaviness; relieved by sitz baths or topical therapyPersistent dull or sharp pain, abdominal fullness; unresponsive to conservative measuresMediumSystemic symptomsRare; occasional weight loss or anemia only with chronic severe bleeding (very uncommon)Common: unexplained weight loss, fatigue, anemia, anorexiaHighPhysical examination (DRE/anoscopy)Soft, compressible vascular cushions; smooth surface; no fixed massHard, irregular, fixed mass; ulceration may be visible; guaiac-positive gloveHighDisease courseChronic, relapsing; symptoms improve with conservative treatmentProgressive; no improvement with conservative therapyMediumNotes: Clinical features were selected based on their frequency of reporting across the included studies (≥30% of studies reporting the feature) and their clinical relevance to the differential diagnosis. Differences in clinical presentation between HD and RC were determined by synthesizing findings from comparative studies and systematic reviews that reported feature-specific prevalence or characteristics. Priority levels (“High”/“edium”) were assigned based on: (1) the strength of evidence supporting the feature’s discriminatory value (number of studies, consistency of findings), (2) clinical utility in primary care settings (ease of assessment, availability of bedside testing), and (3) potential impact on patient outcomes if the feature is overlooked. High-priority features are those with strong evidence and direct implications for timely referral. Clinical Overlap and Differential Diagnosis of Hemorrhoidal Disease and Rectal Cancer Notes: Clinical features were selected based on their frequency of reporting across the included studies (≥30% of studies reporting the feature) and their clinical relevance to the differential diagnosis. Differences in clinical presentation between HD and RC were determined by synthesizing findings from comparative studies and systematic reviews that reported feature-specific prevalence or characteristics. Priority levels (“High”/“edium”) were assigned based on: (1) the strength of evidence supporting the feature’s discriminatory value (number of studies, consistency of findings), (2) clinical utility in primary care settings (ease of assessment, availability of bedside testing), and (3) potential impact on patient outcomes if the feature is overlooked. High-priority features are those with strong evidence and direct implications for timely referral. Physical examination remains the cornerstone of differential diagnosis. Digital rectal examination (DRE) and anoscopy can reliably distinguish the two: HD presents as soft, compressible, smooth-surfaced vascular cushions, whereas RC is characterized by a hard, irregular, often fixed mass, frequently with blood on the examining finger.18 The substantial overlap in symptoms stems from the proximity of the two conditions within the same anatomical region and the non-specific nature of many anorectal symptoms.4 Causes and Consequences of Misdiagnosis (Question 2) Understanding why RC is often mistaken for HD is essential for designing effective prevention strategies, particularly in primary care (Table 3). Table 3Risk Factors for Misdiagnosis of Rectal Cancer as Hemorrhoidal DiseaseCategoryRisk FactorClinical ImpactExplanationClinician-relatedClinical inertia / cognitive biasHighOver-attributing symptoms to HD due to its high prevalence; confirmation bias favoring benign diagnosis (especially in primary care)Clinician-relatedUnderuse of DRE / endoscopyHighFailure to perform DRE routinely; delayed referral for endoscopy (more common in primary care due to limited equipment)Patient-relatedDelayed presentationMediumSelf-diagnosis as HD; embarrassment; perception of low cancer risk (eg, in younger patients)System-relatedLack of standardized diagnostic pathwaysMediumAbsence of clear guidelines for evaluating anorectal symptoms; limited access to endoscopy in primary careSystem-relatedLimited clinician trainingLowInsufficient education on anorectal examination and differential diagnosis in primary care training curriculaNotes: Risk factors were identified from studies reporting associations with misdiagnosis or diagnostic delay. Impact levels (“High”/“Medium”/“Low”) reflect the frequency and clinical significance of each factor as reported in the included literature, with “High” indicating factors reported in ≥50% of relevant studies as major contributors to misdiagnosis. In primary care settings, system-related factors classified as “Medium” may function as “High”-risk contributors due to limited resources and training, as noted in multiple included studies. Table 3Risk Factors for Misdiagnosis of Rectal Cancer as Hemorrhoidal DiseaseCategoryRisk FactorClinical ImpactExplanationClinician-relatedClinical inertia / cognitive biasHighOver-attributing symptoms to HD due to its high prevalence; confirmation bias favoring benign diagnosis (especially in primary care)Clinician-relatedUnderuse of DRE / endoscopyHighFailure to perform DRE routinely; delayed referral for endoscopy (more common in primary care due to limited equipment)Patient-relatedDelayed presentationMediumSelf-diagnosis as HD; embarrassment; perception of low cancer risk (eg, in younger patients)System-relatedLack of standardized diagnostic pathwaysMediumAbsence of clear guidelines for evaluating anorectal symptoms; limited access to endoscopy in primary careSystem-relatedLimited clinician trainingLowInsufficient education on anorectal examination and differential diagnosis in primary care training curriculaNotes: Risk factors were identified from studies reporting associations with misdiagnosis or diagnostic delay. Impact levels (“High”/“Medium”/“Low”) reflect the frequency and clinical significance of each factor as reported in the included literature, with “High” indicating factors reported in ≥50% of relevant studies as major contributors to misdiagnosis. In primary care settings, system-related factors classified as “Medium” may function as “High”-risk contributors due to limited resources and training, as noted in multiple included studies. Risk Factors for Misdiagnosis of Rectal Cancer as Hemorrhoidal Disease Notes: Risk factors were identified from studies reporting associations with misdiagnosis or diagnostic delay. Impact levels (“High”/“Medium”/“Low”) reflect the frequency and clinical significance of each factor as reported in the included literature, with “High” indicating factors reported in ≥50% of relevant studies as major contributors to misdiagnosis. In primary care settings, system-related factors classified as “Medium” may function as “High”-risk contributors due to limited resources and training, as noted in multiple included studies. Causes of Misdiagnosis Misdiagnosis results from a complex interplay of clinician-related, patient-related, and health-system factors. Clinical inertia is the single most important driver: clinicians may take a diagnostic “shortcut,” attributing rectal bleeding to the highly prevalent HD without performing DRE to rule out malignancy.15,17 The inadequate use of diagnostic tools further compounded this problem. DRE can detect up to 70% of rectal cancers located within 10 cm of the anal verge; however, it is frequently omitted because of patient discomfort or time constraints.15,17 Anoscopy and colonoscopy are often deferred, especially when symptoms are intermittent. In some primary care settings, < 30% of patients presenting with rectal bleeding undergo colonoscopy, resulting in missed diagnoses.19 Patient behavior also plays a role. Many individuals self-diagnose hemorrhoids and delay seeking medical attention. Younger patients often mistakenly believe that they are not at risk for colorectal cancer, contributing to longer diagnostic delays.20 Embarrassment about anorectal symptoms may cause patients to minimize complaints. Inconsistent diagnostic pathways and the absence of standardized protocols mean that some clinicians do not routinely perform DRE despite guideline recommendations. Finally, early-stage rectal cancers can be clinically silent, and tumors located in the upper rectum may be beyond the reach of a standard DRE, increasing the likelihood of oversight.10 Clinical and Prognostic Consequences Misdiagnoses have far-reaching implications. Treatment delays allow tumors to progress to more advanced stages, dramatically reducing the chance of curative resection. For early-stage disease, five-year survival rates range from 80% to 90%; these fall to approximately 50% for stage III and to only 10% for stage IV disease.4 Delayed diagnosis often necessitates more aggressive multimodal treatment, associated with higher morbidity and mortality. The economic impact was substantial. Advanced RC requires expensive therapies, including chemotherapy, targeted agents, and prolonged hospitalization. Diagnostic delays generate excessive costs from repeated consultations and unnecessary procedures. Advanced RC imposes a markedly higher economic burden than early-stage disease. The quality of life deteriorates considerably when diagnosis is delayed. Patients with advanced disease frequently experience debilitating pain, fatigue, and treatment-related toxicity. The psychological toll—anxiety, depression, and sense of having been let down by the healthcare system—can be profound and long-lasting.21 Populations at Increased Risk of Misdiagnosis Younger adults (≤40 years) represented a high-risk group. Because RC is often perceived as a disease in older individuals, clinicians may be less likely to suspect malignancy in young patients, attributing symptoms to hemorrhoids. However, the incidence of early-onset colorectal cancer (EOCRC) has been increasing by approximately 4–5% annually in recent years,22 and these patients often experience longer diagnostic intervals due to low clinical suspicion and their own tendency to delay seeking care.23,24 An analysis of over one million colonoscopies in the United States showed a substantial rise in EOCRC rates, particularly in the 40–44 age group.25 Similar birth-cohort effects have been observed in Spain, with incidence increasing since the 1990s.26 A comprehensive review of EOCRC highlights that young patients often present with more advanced stage and aggressive tumor biology.27 Patients with a history of hemorrhoids may also be at heightened risk, as both clinicians and patients may assume that new or worsening symptoms represent a recurrence of the benign condition rather than a new malignant process. The absence of a family history of colorectal cancer can itself be a risk factor for misdiagnosis, as it may lower the threshold for considering malignancy. Because the majority of RC occur in individuals without a family history, reliance on family history as a screening trigger is a dangerous misconception. Early Detection Strategies (Question 3) Timely detection of RC is the most effective way to improve patient outcomes. A range of screening tools are available, from basic physical examinations to advanced endoscopic and molecular methods. Figure 3 summarizes the clinical diagnostic pathway, common causes of misdiagnosis, and standardized early detection workflow for patients with anorectal symptoms in primary care.Figure 3Diagnostic workflow, misdiagnosis causes and early detection pathway for patients with anorectal symptoms. Flowchart illustrating the clinical pathway for patients presenting with anorectal symptoms. It summarizes common causes of misdiagnosis and standardized early detection procedures recommended for primary care settings. This flowchart was created using KnowS Professional Edition 8X; the clinical decision nodes and pathways are derived from evidence synthesized in this systematic review.Flowchart of anorectal symptom pathways: misdiagnosis vs standard detection.The flowchart illustrates two pathways for patients with anorectal symptoms such as rectal bleeding, altered bowel habits, or anorectal discomfort. The left side shows the misdiagnosis pathway, starting with clinical inertia and insufficient examination, leading to misdiagnosis as hemorrhoidal disease, delayed diagnosis, tumor progression and resulting in advanced rectal cancer with poor prognosis. The right side depicts the standard detection pathway, beginning with primary care initial assessment using routine digital rectal examination and anoscopy. It branches into benign signs leading to diagnosis and symptomatic treatment of hemorrhoidal disease, or alarm signs and suspicious lesions leading to stratified screening with options like FIT test, flexible sigmoidoscopy, colonoscopy and AI-assisted endoscopy. This pathway results in early diagnosis, timely intervention, improved survival rate and better quality of life. Diagnostic workflow, misdiagnosis causes and early detection pathway for patients with anorectal symptoms. Flowchart illustrating the clinical pathway for patients presenting with anorectal symptoms. It summarizes common causes of misdiagnosis and standardized early detection procedures recommended for primary care settings. This flowchart was created using KnowS Professional Edition 8X; the clinical decision nodes and pathways are derived from evidence synthesized in this systematic review. Basic Physical Examination DRE and anoscopy constitute the first line of defense. These simple, inexpensive, and non-invasive techniques can be performed in primary care with minimal equipment. DRE should be performed routinely in all patients presenting with anorectal symptoms.5 It can detect approximately 70% of RC located within 10 cm of the anal verge. Despite its value, DRE is performed in only approximately 50% of patients with rectal bleeding in primary care; standardizing its use is a straightforward and highly effective way to reduce misdiagnosis.17 Anoscopy and rigid proctoscopy are useful adjunct procedures. Anoscopy allows direct visualization of the anal canal and distal rectum (up to ~5 cm), distinguishing hemorrhoidal cushions from small tumors. Proctoscopy extends visualization to the entire rectum (up to 20 cm) and allows biopsy specimens to be obtained. Both procedures are office-based and should be available in any practice for managing anorectal complaints.10 Endoscopic Screening Endoscopy remains the gold standard for the early detection of RC. Colonoscopy provides complete examination of the entire colorectum. A large-scale meta-analysis of randomized controlled trials reported that colonoscopy reduced colorectal cancer incidence by 20% (RR 0.80; 95% CI 0.77–0.83) and mortality by 26% (RR 0.74; 95% CI 0.69–0.80).28 However, its use in primary care is limited by bowel preparation, cost, and patient acceptance. Colonoscopy is best reserved for patients with abnormal DRE or anoscopy findings, those with warning signs, or individuals at increased risk. Flexible sigmoidoscopy is a less invasive alternative that visualizes the distal colon and rectum (up to approximately 60 cm). It requires no sedation and is well-tolerated, making it a suitable first-line screening tool in primary care.29 Long-term follow-up of a randomized trial showed that once-only flexible sigmoidoscopy significantly reduces CRC incidence and mortality.30 Artificial intelligence (AI)-assisted endoscopy is an emerging development that may enhance detection accuracy. A network meta-analysis of 64 studies (50,834 patients) found a 20% improvement in adenoma detection rate (ADR) with AI (RR 1.20; 95% CI 1.14–1.26).31 A GRADE-assessed meta-analysis of 38 RCTs (29,745 patients) similarly reported an ADR RR of 1.19 and a reduction in adenoma miss rate (RR 0.52).32 Another meta-analysis of 12 RCTs (11,267 patients) showed a polyp detection rate OR of 1.31 (95% CI 1.08–1.59).33 While evidence on advanced lesions remains less certain, AI appears to be a valuable tool to improve colonoscopy quality.34 Simplified versions may eventually become available in primary care to compensate for limited specialist expertise. Non-Invasive Biomarker Testing Noninvasive tests complement endoscopic screening, especially for patients who are unwilling or unable to undergo colonoscopy. The fecal immunochemical test (FIT) detects hemoglobin in stool. A meta-analysis reported that at a 10 µg/g threshold, FIT has a pooled sensitivity of 91.4% (95% CI 89.4–93.6%) and specificity of 78.3% for CRC detection.35 In resource-limited settings, FIT maintains good performance, with pooled sensitivity of 75% (95% CI 64–85%) and specificity of 89%.36 Repeat FIT (two samples) increases sensitivity to 94% in mixed-risk populations and 98% in symptomatic patients.37 Fecal DNA testing combines analysis of DNA mutations and epigenetic alterations; its sensitivity for early-stage CRC (85–90%) is higher than that of FIT, but its specificity (85–90%) is slightly lower and cost greater. It can be used as a second-line test for FIT-positive patients or for those who decline colonoscopy. Among blood-based markers, carcinoembryonic antigen (CEA) is not suitable for early detection because of its low sensitivity in early-stage disease. Circulating tumor DNA (ctDNA) is a promising novel biomarker, with a reported sensitivity of 70–80% and specificity of 95–98% for CRC.38 As costs decrease, ctDNA testing may become feasible for screening high-risk populations in primary care. Combined ctDNA and FIT approaches have shown improved diagnostic accuracy: one study reported an AUC of 0.955 for ctDNA methylation plus fecal occult blood test,39 and another found that adding ctDNA to FIT increased the AUC from 72.5 to 87.2, potentially reducing colonoscopy referrals by 56% or increasing CRC detection by 28%.40 A recent review highlighted that ctDNA is a promising minimally invasive tool, but its high cost currently limits its widespread use.41 Imaging Studies Transrectal ultrasound (TRUS), magnetic resonance imaging (MRI), and computed tomography (CT) are useful in selected patients. TRUS can assess the tumor depth of invasion and lymph node status, aiding the differentiation of benign from malignant lesions. MRI is the preferred modality for the local staging of RC, providing a detailed assessment of tumor invasion and lymph node involvement. Computed tomography (CT) is primarily used to detect distant metastases.42 Risk Stratification and Screening Protocols Risk stratification based on age, family history, and clinical presentation improved screening efficiency. For average-risk individuals, screening is recommended to begin at age 45–50 years.43 Those with a family history of CRC should start at age 40 or 10 years before the age at which the relative was diagnosed, whichever is earlier.16 The NCCN guidelines emphasize a personalized, risk-based approach.39 The 2025 update includes emerging tests such as the Shield blood test and ColoSense.40 The AGA also provides guidance on risk stratification for screening and post-polypectomy surveillance.41,44 Clinical presentation should also inform the screening approach. Patients with any warning signs of RC should undergo an urgent endoscopic evaluation. For those with only non-specific symptoms, initial assessment with DRE and anoscopy is appropriate; if findings are abnormal or high-risk features are present, colonoscopy should be performed.45,46 A fundamental principle of primary care is to “rule out cancer before treating hemorrhoids.” A definitive diagnosis of HD should be made only after a comprehensive evaluation has excluded RC.10 Clinical Practice Recommendations Based on the available evidence synthesized from the 46 included studies, we propose the following recommendations. Each recommendation is accompanied by the supporting evidence level. General Recommendations Perform a Thorough Initial Evaluation All patients presenting with anorectal symptoms should undergo DRE and anoscopy before a diagnosis of HD is made. Colonoscopy should be performed when RC cannot be excluded. (Evidence: consistent recommendations across 5 clinical guidelines and 12 observational studies included in this review; Ramanathan et al, 2024;10 Bates et al, 202515). Standardize DRE Use DRE should be routine for any patient with anorectal symptoms. Regular training should be provided to recognize findings suggestive of RC. (Evidence: Campbell et al, 202417 reported DRE performed in only ~50% of patients with rectal bleeding in primary care; 8 included studies identified underuse of DRE as a major contributor to misdiagnosis). Use Endoscopy Appropriately Patients with warning signs, those over 40 years of age with persistent symptoms, or those with abnormal physical examination findings should undergo colonoscopy. Flexible sigmoidoscopy can serve as a first-line screening tool in average-risk individuals. (Evidence: Wooldrage et al, 202430 [RCT, 21-year follow-up]; Han et al, 202431 [meta-analysis of RCTs]). Implement Risk-Based Screening Based on NCCN and AGA guidelines included in this review, high-risk individuals should receive annual FIT plus flexible sigmoidoscopy every two years; low-risk individuals may be screened with FIT every two years. (Evidence: Ness et al, 2024;39 NCCN 2026;40 Issaka et al, 202341). Educate Patients and Clinicians Patients should understand the significance of rectal bleeding and the importance of timely evaluation. Clinicians should recognize the limitations of symptom-based diagnoses and the value of objective testing. (Evidence: Mksyartinian et al, 2024;6 4 included studies on patient-related delay factors). Primary Care-Specific Recommendations Establish Standardized Diagnostic Pathways Develop protocols for when to perform DRE/anoscopy, identify warning signs, and establish criteria for referral to specialty care. (Evidence: consistent finding across 9 included studies identifying absence of standardized pathways as a system-level risk factor). Ensure Access to Basic Diagnostic Tools DRE and anoscopy equipment and FIT kits should be available in primary care settings where anorectal complaints are managed. (Evidence: 6 included studies identified limited access to diagnostic tools as a barrier; this recommendation is derived from the finding that inadequate use of diagnostic tools was among the top three causes of misdiagnosis). Create Clear Referral Pathways Formal mechanisms for rapid referral of patients with suspicious findings, including timelines and communication protocols, should be established to prevent delays. (Evidence: based on documented consequences of diagnostic delay in 8 included studies). Provide Ongoing Clinician Education Regular training sessions on anorectal examination, differential diagnosis, and recognition of warning signs using case-based formats should be implemented. (Evidence: 5 included studies identified limited clinician training as a contributing factor). Integrate Screening into Community Health Programs Community-based screening initiatives using FIT as a primary tool, with risk stratification for high-risk individuals, may improve early detection rates. (Evidence: Cheney et al, 2025;36 based on FIT performance data from included meta-analyses). Explore Simplified AI-Assisted Tools Investigate clinical decision aids and anoscopic image recognition systems to support diagnostic accuracy when specialist access is limited. (Evidence: based on preliminary data from AI meta-analyses included in this review31–33). Limitations This study had several limitations. First, randomized controlled trials are scarce in diagnostic research, which limits causal inferences. Second, fewer than 30% of the included studies were conducted in primary care settings, where most diagnostic decisions occur, thus limiting generalizability. Third, emerging technologies, such as AI-assisted endoscopy and ctDNA testing, are supported by preliminary studies only; prospective validation in primary care is needed. Fourth, restrictions on English-language publications may have introduced a language bias. Finally, heterogeneity in study design and outcome definitions precluded a quantitative meta-analysis of certain outcomes. Conclusions Our findings are consistent with previous literature that identified overlapping symptoms as the primary driver of diagnostic delay, but extend the evidence by quantifying the contribution of system-level factors such as limited access to endoscopy and absence of standardized diagnostic pathways in primary care. Compared to earlier reviews that focused predominantly on specialist settings, our synthesis highlights that the majority of misdiagnoses occur not because differentiation is inherently difficult, but because basic examinations are omitted. The substantial overlap in the symptoms between HD and RC creates a challenging diagnostic landscape. Primary care settings bear a disproportionate share of misdiagnosis, often not because differentiation is inherently difficult, but because basic examinations such as DRE and anoscopy are omitted. This problem can be addressed through relatively low-cost interventions. Misdiagnosis leads to treatment delays, tumor progression, reduced survival, and increased physical, psychological, and economic burden. Key contributing factors include clinical inertia, the underuse of essential diagnostic tools, and delayed patient presentation. Current early detection strategies include physical examination, endoscopic screening, and noninvasive biomarker testing. A combination of risk stratification, basic physical examination, and noninvasive testing, supported by streamlined referral pathways, can significantly improve early detection rates in primary care. By implementing risk-stratified screening protocols, standardizing diagnostic workflows, and strengthening patient and clinician education, it is possible to reduce misdiagnoses and improve outcomes. Future research should focus on developing highly sensitive and specific biomarkers, validating AI applications in real-world primary care, and establishing standardized clinical pathways that are adaptable to different healthcare systems. Improving access to screening equipment and strengthening primary care capacity in low- and middle-income countries remains an urgent priority. Despite the diagnostic challenges posed by overlapping symptoms, heightened clinical vigilance, adherence to basic diagnostic protocols, and rational use of screening strategies can substantially reduce the misdiagnosis of RC, improve early detection, and ultimately enhance patient outcomes while reducing the global burden of this disease.